These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22136831)
1. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Kitano M; Millo C; Rahbari R; Herscovitch P; Gesuwan K; Webb RC; Venkatesan AM; Phan GQ; Hughes MS; Libutti SK; Nilubol N; Linehan WM; Kebebew E Surgery; 2011 Dec; 150(6):1122-8. PubMed ID: 22136831 [TBL] [Abstract][Full Text] [Related]
2. Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678 [TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450 [TBL] [Abstract][Full Text] [Related]
5. The utility of Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055 [TBL] [Abstract][Full Text] [Related]
7. Potential value of EUS in pancreatic surveillance of VHL patients. van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551 [TBL] [Abstract][Full Text] [Related]
8. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985 [TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. Weisbrod AB; Kitano M; Thomas F; Williams D; Gulati N; Gesuwan K; Liu Y; Venzon D; Turkbey I; Choyke P; Yao J; Libutti SK; Nilubol N; Linehan WM; Kebebew E J Am Coll Surg; 2014 Feb; 218(2):163-9. PubMed ID: 24440063 [TBL] [Abstract][Full Text] [Related]
10. Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Keutgen XM; Hammel P; Choyke PL; Libutti SK; Jonasch E; Kebebew E Nat Rev Clin Oncol; 2016 Sep; 13(9):537-49. PubMed ID: 27030075 [TBL] [Abstract][Full Text] [Related]
11. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Libutti SK; Choyke PL; Alexander HR; Glenn G; Bartlett DL; Zbar B; Lubensky I; McKee SA; Maher ER; Linehan WM; Walther MM Surgery; 2000 Dec; 128(6):1022-7;discussion 1027-8. PubMed ID: 11114638 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263 [TBL] [Abstract][Full Text] [Related]
13. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887 [TBL] [Abstract][Full Text] [Related]
14. Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. Weisbrod AB; Liewehr DJ; Steinberg SM; Patterson EE; Libutti SK; Linehan WM; Nilubol N; Kebebew E Ann Surg Oncol; 2012 Jun; 19(6):2054-9. PubMed ID: 22350603 [TBL] [Abstract][Full Text] [Related]
16. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. Tamura K; Nishimori I; Ito T; Yamasaki I; Igarashi H; Shuin T World J Gastroenterol; 2010 Sep; 16(36):4515-8. PubMed ID: 20857520 [TBL] [Abstract][Full Text] [Related]
18. Laparoscopic organ-sparing resection of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. von Dücker L; Walz MK; Voss C; Arnold G; Eng C; Neumann HP World J Surg; 2011 Mar; 35(3):563-7. PubMed ID: 21181474 [TBL] [Abstract][Full Text] [Related]
19. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940 [TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT detects clinically occult pancreatic cancer in a case of Von Hippel-Lindau syndrome. Kulkarni M; Purandare N; Zade A; Agrawal A; Shah S; Rangarajan V Clin Nucl Med; 2013 Jul; 38(7):e302-3. PubMed ID: 23486326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]